Taro Pharmaceutical Industries (NYSE:TARO) Stock Crosses Below 200-Day Moving Average of $36.24

Taro Pharmaceutical Industries Ltd. (NYSE:TARO) crossed below its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $36.24 and traded as low as $35.52. Taro Pharmaceutical Industries shares last traded at $35.83, with a volume of 18,427 shares traded.

Analyst Upgrades and Downgrades

Separately, StockNews.com began coverage on Taro Pharmaceutical Industries in a report on Thursday, October 5th. They set a “strong-buy” rating for the company.

Taro Pharmaceutical Industries Price Performance

The company has a 50 day simple moving average of $35.97 and a 200-day simple moving average of $36.24.

Taro Pharmaceutical Industries (NYSE:TARO) last issued its earnings results on Thursday, October 26th. The company reported $0.38 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.18 by $0.20. The business had revenue of $148.20 million during the quarter, compared to analyst estimates of $161.14 million. Taro Pharmaceutical Industries had a return on equity of 2.50% and a net margin of 5.53%. As a group, equities analysts expect that Taro Pharmaceutical Industries Ltd. will post 1.38 EPS for the current year.

Institutional Trading of Taro Pharmaceutical Industries

Several hedge funds and other institutional investors have recently bought and sold shares of TARO. Ameritas Investment Partners Inc. purchased a new stake in shares of Taro Pharmaceutical Industries during the second quarter valued at approximately $26,000. UBS Group AG boosted its stake in shares of Taro Pharmaceutical Industries by 71.6% during the second quarter. UBS Group AG now owns 925 shares of the company’s stock valued at $34,000 after purchasing an additional 386 shares during the period. Bank of America Corp DE boosted its stake in shares of Taro Pharmaceutical Industries by 126.5% during the first quarter. Bank of America Corp DE now owns 1,506 shares of the company’s stock valued at $37,000 after purchasing an additional 841 shares during the period. Royal Bank of Canada boosted its stake in shares of Taro Pharmaceutical Industries by 664.0% during the second quarter. Royal Bank of Canada now owns 1,039 shares of the company’s stock valued at $39,000 after purchasing an additional 903 shares during the period. Finally, Tower Research Capital LLC TRC boosted its stake in shares of Taro Pharmaceutical Industries by 5,988.2% during the second quarter. Tower Research Capital LLC TRC now owns 1,035 shares of the company’s stock valued at $39,000 after purchasing an additional 1,018 shares during the period. Hedge funds and other institutional investors own 11.45% of the company’s stock.

Taro Pharmaceutical Industries Company Profile

Taro Pharmaceutical Industries Ltd., a science-based pharmaceutical company, develops, manufactures, and markets prescription and over-the-counter pharmaceutical products in the United States, Canada, Israel, and internationally. The company also develops and manufactures active pharmaceutical ingredients primarily for use in its finished dosage form products.